Novartis plans to give up to 100 doses annually of Zolgensma, its costly gene therapy for spinal muscular atrophy (SMA), free-of-charge to eligible young children outside the U.S. with this progressive, neuromuscular ... Read more

It’s not a secret that I’m not a big fan of winter weather. But that doesn’t mean I don’t like a few things about this time of year. Specifically, ... Read more

Novartis plans to give up to 100 doses annually of Zolgensma, its costly gene therapy for spinal muscular atrophy (SMA), free-of-charge to eligible young children outside the U.S. with this progressive, neuromuscular ... Read more

This time of year is my family’s time to shine — literally. Our house sits on a hill on a narrow street that runs parallel to the main road. ... Read more

I’ve been in awe of spectacular night skies for as long as I can remember. When our family moved to the mountains of North Carolina (close to the stunning ... Read more

The parents of two babies treated in July with Zolgensma, the first gene therapy approved for spinal muscular atrophy or any neuromuscular disease, are confident they made the right choice ... Read more

The seats in the high school auditorium filled quickly before Ella’s first concert with the Young Naperville Singers (YNS) began. We had spent the morning getting ready for the ... Read more

There are only a couple of weeks left in the year and although I’m excited for Christmas, I’m also ready for this year to end. Let’s bring back the ... Read more

Four years ago, I put on my big-boy pants and finally learned how to feed myself. Throughout my high school and college years, I was too lazy to pick ... Read more

Lowering the expression of the EphA4 gene — a gene that plays a major role in many neurological disorders — is not enough to improve motor function and survival in ... Read more